AMPK Activator O304 A Novel Potential Treatment For Diabetic Kidney Disease | Latest News RSS feed

AMPK Activator O304 A Novel Potential Treatment For Diabetic Kidney Disease - Latest News

AMPK Activator O304 A Novel Potential Treatment for Diabetic Kidney Disease

Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard ... read more

Poxel Announces Third Quarter and Nine Months 2018 Financial Update

We believe that PXL770 has the potential ... diabetic treatment paradigm, including monotherapy or as an add-on to other glucose lowering therapies. About PXL770 PXL770 is a first-in-class direct aden... read more

Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update

PXL065, an MPC inhibitor and PXL770, a direct AMPK activator, are drug candidates that have the potential to treat the underlying root causes of liver disease ... a drug approved for the treatment of ... read more

Looking for another news?

Study suggests well-known growth suppressor actually fuels lethal brain cancers

Scientists report in Nature Cell Biology that tumor growth was reduced when the researchers genetically inhibited AMPK, suggesting it may be a potential treatment strategy ... cell metabolism called A... read more

Poxel Announces Positive Top Line Results for Its Antidiabetic Agent Imeglimin in a Phase 2b Dose-Ranging Trial

LYON, France--(BUSINESS WIRE)--Poxel SA today announced that Imeglimin, a novel ... Type 2 Diabetes candidates, including Imeglimin, a direct activator of AMPK, which is close to phase 1 development, ... read more

The multifactorial role of leptin in driving the breast cancer microenvironment

Finally, future perspectives and clinical applications in which leptin and the leptin receptor are considered as potential therapeutic targets ... for therapeutic intervention in breast cancer treatme... read more

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries...

Activities in 2018 to support initiation of the Phase 3 program will include differentiation studies to confirm imeglimin's potential in sensitive patient populations, such as those with chronic kidne... read more

Poxel's Anti-diabetic Imeglimin Confirms Its Unique Mechanism of Action in Type 2 Diabetic Patients

No other single agent impacts the three main organs involved in this chronic disease, which means Imeglimin can be combined with any current diabetes treatments. This potential was ... A direct activa... read more

Dr. Faramarz Ismail-Beigi

Faramarz Ismail-Beigi is an endocrinologist in Cleveland ... one of 19 at University Hospitals Cleveland Medical Center who specialize in Endocrinology, Diabetes & Metabolism. read more

Scientists block RNA silencing protein in liver to prevent obesity and diabetes in mice

Credit: Vossman/ Wikipedia Obesity and its related ailments like type 2 diabetes and fatty liver disease pose a major global health ... "This allows us to explore the potential of finding a novel ther... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us